Certain Shares of Sensidose AB are subject to a Lock-Up Agreement Ending on 9-FEB-2023. These Shares will be under lockup for 276 days starting from 9-MAY-2022 to 9-FEB-2023.

Details:
Arkonek Invest AB (Lars-Åke Adolfsson), Myacom Investment AB (Per Vasilis), Jungfrutomten Värdeinvest Aktiebolag (Johan Markman), CapMate Aktiebolag (Gerhard Dal), Råsunda forvaltning aktiebolag (Per Nilsson, Chairman of the Board of Sensidose), Optiga AB (Lars Tenerz, Board member of Sensidose), Jack Spira (CEO of Sensidose), Inspira Medical AB (Jack Spira, CEO of Sensidose), Kristofer Svensson (CFO of Sensidose), Sten-Magnus Aquilonius (Sensidose founder), Christine Aquilonius and Per Vasilis have entered into lock-up agreements prior to the planned new issue and listing. This corresponds to approximately 40.66 percent of the shares in the Company after a fully subscribed new issue. The agreement means that they undertake not to sell more than a maximum of 10 percent of their existing holdings in the Company during the first 9 months from the first trading day. The lock-up agreement covers all shares in the Company that the shareholder currently owns and will own until the first trading day on Spotlight. The lock-up agreement does not cover the warrants of series TO 1. The company's largest shareholder, BWG Invest Sàrl (William Gunnarsson), is not covered by the lock-up agreement.